Donald Nicholson
About Donald Nicholson
Donald Nicholson is the Executive Chairman of Nimbus Therapeutics and a former VP at Merck, with extensive experience in drug discovery across various therapeutic areas.
Donald Nicholson Executive Chairman
Donald Nicholson serves as the Executive Chairman. With a background in biotechnology, he has extensive experience in managing high-profile positions in the pharmaceutical and biotech industries.
Former CEO of Nimbus Therapeutics
Donald Nicholson was the CEO of Nimbus Therapeutics, a company specializing in computational sciences-based drug discovery. Under his leadership, Nimbus Therapeutics focused on developing treatments in immunology, metabolic diseases, and oncology.
Donald Nicholson at Merck
With a 25-year tenure at Merck, Donald Nicholson held the role of VP & Worldwide Discovery Head. He was responsible for multiple therapeutic areas, including immunology, respiratory, endocrine, bone, muscle, urology, and anemia. His extensive experience at Merck provided him with deep insights into drug discovery and development.
Education and Training
Donald Nicholson received his Ph.D. in Biochemistry from the University of Western Ontario. He subsequently trained as an MRC post-doctoral fellow at the University of Munich, which further advanced his expertise in biochemistry and medical research.
Publications and Honors
Donald Nicholson has co-authored over 150 publications, showcasing his significant contributions to scientific research. He is a recipient of multiple academic and professional honors, reflecting his standing in the scientific community.
Board Memberships
Donald Nicholson is a member of the Board of Directors for several companies, including Kymera, Generation Bio, Jnana, and NodThera. His extensive experience in the biotech and pharmaceutical sectors makes him a valuable asset to these organizations.